Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCOCO: Two vs Three Cycles of Neoadjuvant Chemotherapy in Advanced Ovarian, Fallopian and Primary Peritoneal Cancer
NCT03693248Phase 3Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival up to 60 months. Status: unknown.
02
Drugs
paclitaxelcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03693248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693248.